SEC Filing | Sage Therapeutics, Inc.

SCHEDULE 13G

CUSIP No.

78667J108

1

Names of Reporting Persons

BB Biotech AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,178,503.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,178,503.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,178,503.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

11

Percent of class represented by amount in row (9)

1.9 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No.

78667J108

1

Names of Reporting Persons

Biotech Target N.V.

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NETHERLANDS ANTILLES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,178,503.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,178,503.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,178,503.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

11

Percent of class represented by amount in row (9)

1.9 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Sage Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

215 First Street, Cambridge, MA 02141

Item 2.

(a)

Name of person filing:

BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Target N.V. ("Biotech Target")

(b)

Address or principal business office or, if none, residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland Biotech Target N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curacao

(c)

Citizenship:

BB Biotech AG: Switzerland Biotech Target N.V.: Curacao

(d)

Title of class of securities:

Common Stock

(e)

CUSIP No.:

78667J108

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

1,178,503

(b)

Percent of class:

1.9% %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote:

1,178,503

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

1,178,503

Item 5.

Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

This statement is filed jointly by BB Biotech and Biotech Target, Biotech Target is a wholly-owned subsidiary of BB Biotech.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG

Signature:	/s/ Martin Gubler
Name/Title:	Martin Gubler
Date:	01/16/2025

Signature:	/s/ Ivo Betschart
Name/Title:	Ivo Betschart
Date:	01/16/2025

Biotech Target N.V.

Signature:	/s/ Jan Bootsma
Name/Title:	Jan Bootsma
Date:	01/16/2025

Signature:	/s/ Hugo van Neutegem
Name/Title:	Hugo van Neutegem
Date:	01/16/2025

Exhibit Information

Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.* *Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.'s Schedule 13G filed with the Securities and Exchange Commission on February 17, 2023.